Design and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains

ACS Medicinal Chemistry Letters

Volumn 8, Issue 8, 2017, Pages 847-852

  Millan, David S ^a   Kayser Bricker, Katherine J ^b   Martin, Matthew W ^a   Talbot, Adam C ^b   Schiller, Shawn E R ^a   Herbertz, Torsten ^a   Williams, Grace L ^a   Luke, George P ^b   Hubbs, Stephen ^b   Alvarez Morales, Monica A ^a   Cardillo, Daniel ^a   Troccolo, Paul ^a   Mendes, Rachel L ^a   McKinnon, Crystal ^a  

^a Forma Therapeutics   (United States)

^b FORMA Therapeutics Inc   (United States)

Author keywords

BET; BRD4; Bromodomains

Indexed keywords

BENZOPIPERAZINE DERIVATIVE; BROMODOMAIN INHIBITOR; FT 001; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CELL ACTIVITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOPHILICITY; MOUSE; MYELOMONOCYTIC LEUKEMIA; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TUMOR XENOGRAFT;

EID: 85027239659     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.7b00191     Document Type: Article

References (20)

1. Wu, S.-Y.; Chiang, C.-M. The Double Bromodomain-Containing Chromatin Adaptor Brd4 and Transcriptional Regulation J. Biol. Chem. 2007, 282 (18) 13141-13145 10.1074/jbc.R700001200
2. Fu, L.-L.; Tian, M.; Li, X.; Li, J.-J.; Huang, J.; Ouyang, L.; Zhang, Y.; Liu, B. Inhibition of BET Bromodomains as a Therapeutic Strategy for Cancer Drug Discovery Oncotarget 2015, 6 (8) 5501-5516 10.18632/oncotarget.3551
3. Arrowsmith, C. H.; Bountra, C.; Fish, P. V.; Lee, K.; Schapira, M. Epigenetic Protein Families: A New Frontier for Drug Discovery Nat. Rev. Drug Discovery 2012, 11 (5) 384-400 10.1038/nrd3674
4. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.-W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of Inflammation by a Synthetic Histone Mimic Nature 2010, 468 (7327) 1119-1123 10.1038/nature09589
5. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective Inhibition of BET Bromodomains Nature 2010, 468 (7327) 1067-1073 10.1038/nature09504
6. Seal, J.; Lamotte, Y.; Donche, F.; Bouillot, A.; Mirguet, O.; Gellibert, F.; Nicodeme, E.; Krysa, G.; Kirilovsky, J.; Beinke, S.; McCleary, S.; Rioja, I.; Bamborough, P.; Chung, C.-W.; Gordon, L.; Lewis, T.; Walker, A. L.; Cutler, L.; Lugo, D.; Wilson, D. M.; Witherington, J.; Lee, K.; Prinjha, R. K. Identification of a Novel Series of BET Family Bromodomain Inhibitors: Binding Mode and Profile of I-BET151 (GSK1210151A) Bioorg. Med. Chem. Lett. 2012, 22 (8) 2968-2972 10.1016/j.bmcl.2012.02.041
7. Gosmini, R.; Nguyen, V. L.; Toum, J.; Simon, C.; Brusq, J.-M. G.; Krysa, G.; Mirguet, O.; Riou-Eymard, A. M.; Boursier, E. V.; Trottet, L.; Bamborough, P.; Clark, H.; Chung, C.; Cutler, L.; Demont, E. H.; Kaur, R.; Lewis, A. J.; Schilling, M. B.; Soden, P. E.; Taylor, S.; Walker, A. L.; Walker, M. D.; Prinjha, R. K.; Nicodème, E. The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 up-Regulator and Selective BET Bromodomain Inhibitor J. Med. Chem. 2014, 57 (19) 8111-8131 10.1021/jm5010539
8. Albrecht, B. K.; Gehling, V. S.; Hewitt, M. C.; Vaswani, R. G.; Côté, A.; Leblanc, Y.; Nasveschuk, C. G.; Bellon, S.; Bergeron, L.; Campbell, R.; Cantone, N.; Cooper, M. R.; Cummings, R. T.; Jayaram, H.; Joshi, S.; Mertz, J. A.; Neiss, A.; Normant, E.; O'Meara, M.; Pardo, E.; Poy, F.; Sandy, P.; Supko, J.; Sims, R. J.; Harmange, J.-C.; Taylor, A. M.; Audia, J. E. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials J. Med. Chem. 2016, 59 (4) 1330-1339 10.1021/acs.jmedchem.5b01882
9. Picaud, S.; Wells, C.; Felletar, I.; Brotherton, D.; Martin, S.; Savitsky, P.; Diez-Dacal, B.; Philpott, M.; Bountra, C.; Lingard, H.; Fedorov, O.; Müller, S.; Brennan, P. E.; Knapp, S.; Filippakopoulos, P. RVX-208, an Inhibitor of BET Transcriptional Regulators with Selectivity for the Second Bromodomain Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (49) 19754-19759 10.1073/pnas.1310658110
10. Picaud, S.; Da Costa, D.; Thanasopoulou, A.; Filippakopoulos, P.; Fish, P. V.; Philpott, M.; Fedorov, O.; Brennan, P.; Bunnage, M. E.; Owen, D. R.; Bradner, J. E.; Taniere, P.; O'Sullivan, B.; Müller, S.; Schwaller, J.; Stankovic, T.; Knapp, S. PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains Cancer Res. 2013, 73 (11) 3336-3346 10.1158/0008-5472.CAN-12-3292
11. Sarthy, A.; Li, L.; Albert, D. H.; Lin, X.; Scott, W.; Faivre, E.; Bui, M. H.; Huang, X.; Wilcox, D. M.; Magoc, T.; Buchanan, F. G.; Tapang, P.; Sheppard, G. S.; Wang, L.; Fidanze, S. D.; Pratt, J.; Liu, D.; Hasvold, L.; Hessler, P.; Uziel, T.; Lam, L.; Rajaraman, G.; Fang, G.; Elmore, S. W.; Rosenberg, S. H.; McDaniel, K.; Kati, W.; Shen, Y. Abstract 4718: ABBV-075, a Novel BET Family Bromodomain Inhibitor, Represents a Promising Therapeutic Agent for a Broad Spectrum of Cancer Indications Cancer Res. 2016, 76 (14 Supplement) 4718 10.1158/1538-7445.AM2016-4718
12. Ferri, E.; Petosa, C.; McKenna, C. E. Bromodomains: Structure, Function and Pharmacology of Inhibition Biochem. Pharmacol. 2016, 106, 1-18 10.1016/j.bcp.2015.12.005
13. Romero, F. A.; Taylor, A. M.; Crawford, T. D.; Tsui, V.; Côté, A.; Magnuson, S. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors J. Med. Chem. 2016, 59 (4) 1271-1298 10.1021/acs.jmedchem.5b01514
14. Liu, Z.; Wang, P.; Chen, H.; Wold, E. A.; Tian, B.; Brasier, A. R.; Zhou, J. Drug Discovery Targeting Bromodomain-Containing Protein 4 J. Med. Chem. 2017, 60 (11) 4533-4558 10.1021/acs.jmedchem.6b01761
15. Theodoulou, N. H.; Tomkinson, N. C.; Prinjha, R. K.; Humphreys, P. G. Clinical Progress and Pharmacology of Small Molecule Bromodomain Inhibitors Curr. Opin. Chem. Biol. 2016, 33, 58-66 10.1016/j.cbpa.2016.05.028
16. Abedin, S. M.; Boddy, C. S.; Munshi, H. G. BET Inhibitors in the Treatment of Hematologic Malignancies: Current Insights and Future Prospects OncoTargets Ther. 2016, 9, 5943-5953 10.2147/OTT.S100515
17. Chung, C.-W.; Dean, A. W.; Woolven, J. M.; Bamborough, P. Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery J. Med. Chem. 2012, 55 (2) 576-586 10.1021/jm201320w
18. Popp, T. A.; Tallant, C.; Rogers, C.; Fedorov, O.; Brennan, P. E.; Müller, S.; Knapp, S.; Bracher, F. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors J. Med. Chem. 2016, 59 (19) 8889-8912 10.1021/acs.jmedchem.6b00774
19. Bair, K. W.; Herbertz, T.; Kauffman, G. S.; Kayser-Bricker, K. J.; Luke, G. P.; Martin, M. W.; Millan, D. S.; Schiller, S. E. R.; Talbot, A. C.; Tebbe, M. J. WO2015/074081, 21 May 2015.
20. Mertz, J. A.; Conery, A. R.; Bryant, B. M.; Sandy, P.; Balasubramanian, S.; Mele, D. A.; Bergeron, L.; Sims, R. J. Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (40) 16669-16674 10.1073/pnas.1108190108